MNKD

SEC source: 0000950170-25-073082 · ownership.xml · nonDerivative · entry 4

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 772,427

F3 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established August 19, 2024.

F4 · price: The weighted average sales price of the reported transaction was $4.68 based on a range of prices between $4.65 and $4.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0000950170-25-073080 · ownership.xml · derivative · entry 5

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,000

Underlying: Common Stock, $0.01 Par Value · 145,000 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F6 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

F6 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

SEC source: 0000950170-25-073080 · ownership.xml · nonDerivative · entry 4

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,096,574

F3 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F4 · balance_after: Includes 1,558 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024.

SEC source: 0000950170-25-073078 · ownership.xml · derivative · entry 5

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 523,000

Underlying: Common Stock, $0.01 Par Value · 523,000 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F5 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

F5 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

SEC source: 0000950170-25-073078 · ownership.xml · nonDerivative · entry 4

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,612,048

F3 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

SEC source: 0000950170-25-073049 · ownership.xml · derivative · entry 2

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,000

Underlying: Common Stock, $0.01 Par Value · 145,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F4 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

F4 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

SEC source: 0000950170-25-073049 · ownership.xml · nonDerivative · entry 1

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 506,509

F1 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · balance_after: Includes 2,093 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024.

SEC source: 0000950170-25-073046 · ownership.xml · derivative · entry 2

Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,000

Underlying: Common Stock, $0.01 Par Value · 145,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

SEC source: 0000950170-25-073046 · ownership.xml · nonDerivative · entry 1

Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 353,193

F1 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F4 · balance_after: Includes 1,593 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024.

SEC source: 0000950170-25-073081 · ownership.xml · nonDerivative · entry 3

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,086,755

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0000950170-25-073081 · ownership.xml · nonDerivative · entry 2

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,093,196

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0000950170-25-073082 · ownership.xml · nonDerivative · entry 3

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 804,606

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0000950170-25-073082 · ownership.xml · nonDerivative · entry 2

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 816,970

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0000950170-25-073080 · ownership.xml · nonDerivative · entry 3

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 976,016

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0000950170-25-073080 · ownership.xml · nonDerivative · entry 2

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 984,067

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0000950170-25-073078 · ownership.xml · nonDerivative · entry 3

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,184,048

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0000950170-25-073078 · ownership.xml · nonDerivative · entry 2

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,218,942

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0000950170-25-073081 · ownership.xml · nonDerivative · entry 1

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,180,626

F1 · kind: A previously reported restricted stock unit award granted on May 10, 2022 vested on May 10, 2025 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 9, 2025 was not less than the closing price on May 10, 2022 and (ii) MannKind's total shareholder return (TSR) over the period from May 10, 2022 to May 10, 2025 was at the 73.9th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares. The acquisition of 110,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 12, 2022.

SEC source: 0000950170-25-073082 · ownership.xml · nonDerivative · entry 1

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 935,443

F1 · kind: A previously reported restricted stock unit award granted on May 10, 2022 vested on May 10, 2025 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 9, 2025 was not less than the closing price on May 10, 2022 and (ii) MannKind's total shareholder return (TSR) over the period from May 10, 2022 to May 10, 2025 was at the 73.9th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares. The acquisition of 110,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 12, 2022.

SEC source: 0000950170-25-073080 · ownership.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,072,791

F1 · kind: A previously reported restricted stock unit award granted on May 10, 2022 vested on May 10, 2025 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 9, 2025 was not less than the closing price on May 10, 2022 and (ii) MannKind's total shareholder return (TSR) over the period from May 10, 2022 to May 10, 2025 was at the 73.9th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares. The acquisition of 110,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 12, 2022.

SEC source: 0000950170-25-073078 · ownership.xml · nonDerivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,553,896

F1 · kind: A previously reported restricted stock unit award granted on May 10, 2022 vested on May 10, 2025 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 9, 2025 was not less than the closing price on May 10, 2022 and (ii) MannKind's total shareholder return (TSR) over the period from May 10, 2022 to May 10, 2025 was at the 73.9th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 196% of target, resulting in a total share delivery of 609,560 shares. The acquisition of 311,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 12, 2022.

SEC source: 0000950170-25-051315 · ownership.xml · nonDerivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,255,336

F1 · kind: Reporting person transferred 39,500 shares of MNKD common stock to his ex-spouse pursuant to a divorce decree.

SEC source: 0000950170-25-047092 · ownership.xml · nonDerivative · entry 1

Sabella Lauren M · CIK 0001360928 · EVP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 357,849

F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units.

SEC source: 0000950170-25-020295 · ownership.xml · nonDerivative · entry 1

Marasco Dominic · CIK 0002053897 · Pres, Endocrine Business Unit

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,000

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · kind: Four-year vesting schedule with no shares vesting on the first anniversary of the vesting determination date of January 6, 2025 and one-third on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date.

SEC source: 0000950170-24-130728 · ownership.xml · derivative · entry 5

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 22,512 shares

Expires 2027-08-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-130728 · ownership.xml · derivative · entry 4

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 22,512 shares

Expires 2027-08-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-130728 · ownership.xml · derivative · entry 3

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 22,512 shares

Expires 2027-08-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-130728 · ownership.xml · nonDerivative · entry 2

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,075,026

F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 16, 2024.

F2 · price: The weighted average sales price of the reported transaction was $6.89 based on a range of prices between $6.83 and $6.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0000950170-24-130728 · ownership.xml · nonDerivative · entry 1

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,142,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-128986 · ownership.xml · derivative · entry 7

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,575

Underlying: Common Stock, $0.01 Par Value · 17,575 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F5 · kind: Restricted stock unit vested on November 18, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F5 · derivative.exercise_date: Restricted stock unit vested on November 18, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F5 · derivative.expiration_date: Restricted stock unit vested on November 18, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0000950170-24-128986 · ownership.xml · derivative · entry 6

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,512

Underlying: Common Stock, $0.01 Par Value · 22,513 shares

Expires 2027-08-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-128986 · ownership.xml · derivative · entry 5

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,512

Underlying: Common Stock, $0.01 Par Value · 22,513 shares

Expires 2027-08-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-128986 · ownership.xml · derivative · entry 4

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,512

Underlying: Common Stock, $0.01 Par Value · 22,513 shares

Expires 2027-08-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-128986 · ownership.xml · nonDerivative · entry 2

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,075,026

F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 16, 2024.

F2 · price: The weighted average sales price of the reported transaction was $6.76 based on a range of prices between $6.63 and $7.05. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0000950170-24-128986 · ownership.xml · nonDerivative · entry 1

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,142,565

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-124349 · ownership.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 967,191

F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established May 31, 2024.

SEC source: 0000950170-24-121041 · ownership.xml · nonDerivative · entry 1

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 385,416

F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units.

SEC source: 0000950170-24-103683 · ownership.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,022,191

F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established May 31, 2024.

F2 · price: The weighted average sales price of the reported transaction was $6.26 based on a range of prices between $6.19 and $6.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0000950170-24-102517 · ownership.xml · nonDerivative · entry 2

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,047,191

F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established May 31, 2024.

F2 · kind: The weighted average sales price for the transaction reported was $6.32 based on a range of prices between $6.25 and $6.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0000950170-24-102517 · ownership.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,082,191

F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established May 31, 2024.

SEC source: 0000950170-24-102043 · ownership.xml · nonDerivative · entry 4

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,294,836

SEC source: 0000950170-24-102043 · ownership.xml · nonDerivative · entry 3

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,379,942

F2 · kind: Shares gifted as a charitable donation.

SEC source: 0000950170-24-102041 · ownership.xml · nonDerivative · entry 2

Binder Steven B. · CIK 0001712601 · EVP Special Projects

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,075,026

F2 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 18, 2023.

SEC source: 0000950170-24-102040 · ownership.xml · nonDerivative · entry 2

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 829,843

F2 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established September 5, 2023.

SEC source: 0000950170-24-102043 · ownership.xml · nonDerivative · entry 2

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,398,942

F2 · kind: Shares gifted as a charitable donation.

SEC source: 0000950170-24-102042 · ownership.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,127,191

F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units.

SEC source: 0000950170-24-102043 · ownership.xml · nonDerivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,412,836

F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units.

SEC source: 0000950170-24-102041 · ownership.xml · nonDerivative · entry 1

Binder Steven B. · CIK 0001712601 · EVP Special Projects

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,080,081

F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units.

SEC source: 0000950170-24-102040 · ownership.xml · nonDerivative · entry 1

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 835,396

F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units.

SEC source: 0000950170-24-084405 · ownership.xml · nonDerivative · entry 3

Binder Steven B. · CIK 0001712601 · EVP Special Projects

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,100,860

F3 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 18, 2023.